Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, signaling a newer version of the page content. This appears to be a maintenance update rather than a substantive change to the study details.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision: v3.6.2 replaces the previous v3.6.0 on the page, signaling an update to the study record. This reflects a version change rather than a substantive alteration to study details.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page now displays a 'No longer looking for participants' notice and adds new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) to help users navigate the study details. The Intervention/Treatment header formatting is updated and the prior Revision label (v3.5.5) was removed, reflecting a styling and version update.SummaryDifference0.5%

- Check44 days agoChange DetectedRevision identifier updated from v3.5.4 to v3.5.5, indicating a newer build of the page. This likely reflects minor updates or fixes rather than changes to the study content.SummaryDifference0.1%

- Check66 days agoChange DetectedA new Revision: v3.5.4 tag was added, replacing the prior Revision: v3.5.3. This indicates a small update to the page's versioning information.SummaryDifference0.1%

- Check87 days agoChange DetectedThe site’s UI/engine “Revision” value has been updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.